Advancement in treatment options for your cervical cancer patients: Final analysis data of KEYNOTE-826
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
This infographic summarises the eligible patient for treatment with KEYTRUDA® (pembrolizumab) in combination with chemotherapy with or without bevacizumab for patients with persistent, recurrent or metastatic CPS ≥1 cervical cancer and the key outcomes from the KEYNOTE-826 Final analysis.1
This content in intended to be viewed online, it is not intended to be printed.
Refer to the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.
More information about KEYTRUDA® (pembrolizumab) in cervical cancer
Reference
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
